Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

3.750 +0.580 (+18.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,375,135
Open 3.200
Bid (Size) 3.700 (10)
Ask (Size) 3.740 (4)
Prev. Close 3.170
Today's Range 3.171 - 3.990
52wk Range 2.680 - 17.00
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
From The Rosen Law Firm PA
Via GlobeNewswire

Performance

YTD
-70.1%
-70.1%
1 Month
-59.6%
-59.6%
3 Month
-60.1%
-60.1%
6 Month
-73.3%
-73.3%
1 Year
-62.7%
-62.7%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
From Pomerantz LLP
Via GlobeNewswire
From Shriram Properties, Havells To Vesuvius: SEBI RA Sees 15% To 30% Upside In These Six Stocks
Via Stocktwits
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc.
From Robbins LLP
Via GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)
From Bernstein Liebhard LLP
Via GlobeNewswire
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Via Benzinga
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline
From Bleichmar Fonti & Auld LLP
Via Business Wire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
From The Rosen Law Firm PA
Via GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL
From The Rosen Law Firm, P.A.
Via Business Wire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors
From Kirby McInerney LLP
Via GlobeNewswire
Which stocks are experiencing notable movement on Wednesday?
Via Chartmill
This Centene Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi, LLP
Via Business Wire
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm
From Bleichmar Fonti & Auld LLP
Via Business Wire
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Falls Over 100 Points; Coca-Cola Posts Upbeat Earnings
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?
Yes, Replimune Group, Inc. - Common Stock is publicly traded.
What exchange does Replimune Group, Inc. - Common Stock trade on?
Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Replimune Group, Inc. - Common Stock?
The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
What is the current price of Replimune Group, Inc. - Common Stock?
The current price of Replimune Group, Inc. - Common Stock is 3.750
When was Replimune Group, Inc. - Common Stock last traded?
The last trade of Replimune Group, Inc. - Common Stock was at 07/29/25 04:00 PM ET
What is the market capitalization of Replimune Group, Inc. - Common Stock?
The market capitalization of Replimune Group, Inc. - Common Stock is 175.40M
How many shares of Replimune Group, Inc. - Common Stock are outstanding?
Replimune Group, Inc. - Common Stock has 175M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.